Scrip 100: Statin debate set to run and run
This article was originally published in Scrip
Earlier this year, as expected, final guidance on the use of statins in individuals with a relatively low risk of cardiovascular disease (CVD) was issued by NICE, the health technology body for England and Wales. The new guidance lowered the treatment threshold from a 20% risk of CVD over ten years to 10%, and was published as it emerged that the use of statins had in any case expanded enormously – from 21.6 million prescriptions in England in 2003 to 63.1 million prescriptions in 2013.
You may also be interested in...
The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.
Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.
The market for minimally invasive weight loss devices will reach more than $290 million by 2021, according to a new report from Informa’s Meddevicetracker. Issues relating to laparoscopic adjustable gastric banding systems will result in a greater emphasis being placed on intragastric balloons, which will grow at twice the segment average.